Search

Your search keyword '"Popat, Sanjay"' showing total 1,160 results
Start Over Author "Popat, Sanjay"
1,160 results on '"Popat, Sanjay"'

206. Distinct pancreatic and neuronal Lung Carcinoid molecular subtypes revealed by integrative omic analysis

Author

Domingo-Sabugo, Clara, primary, Willis-Owen, Saffron A.G., additional, Mandal, Amit, additional, Nastase, Anca, additional, Dwyer, Sarah, additional, Brambilla, Cecilia, additional, Gálvez, José Héctor, additional, Zhuang, Qinwei, additional, Popat, Sanjay, additional, Eveleigh, Robert, additional, Munter, Markus, additional, Lim, Eric, additional, Nicholson, Andrew G., additional, Lathrop, Mark, additional, Cookson, William O.C., additional, and Moffatt, Miriam F., additional

Published
2021
Full Text
View/download PDF

207. Abstract LB138: UpSwinG: real-world, non-interventional cohort study on TKI activity in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC with uncommon mutations

Author

Miura, Satoru, primary, Hsia, Te-Chun, additional, Hung, Jen-Yu, additional, Jung, Hyun Ae, additional, Shih, Jin-Yuan, additional, Yang, Tsung-Ying, additional, Park, Cheol-Kyu, additional, Lee, Seung Hyeun, additional, Okamoto, Tatsuro, additional, Ahn, Hee Kyung, additional, Lee, Yong Chul, additional, Sato, Yuki, additional, Lee, Sung Sook, additional, Mascaux, Céline, additional, Daoud, Hasan, additional, Märten, Angela, additional, and Popat, Sanjay, additional

Published
2021
Full Text
View/download PDF

209. Detection of tier 1 variants with circulating tumour (ct) DNA next generation sequencing (NGS) in UK non-small cell lung cancer (NSCLC) patients

Author

Milner-Watts, Charlotte, primary, Lyons, Hannah, additional, Cui, Wanyuan, additional, Yousaf, Nadia, additional, Minchom, Anna, additional, Bhosle, Jaishree, additional, Davidson, Michael, additional, Scott, Sophie, additional, Faull, Iris, additional, Nagy, Rebecca, additional, O’Brien, Mary, additional, and Popat, Sanjay, additional

Published
2021
Full Text
View/download PDF

211. An audit of compliance with NOLCP in the GLH era

Author

Ly, Fabrice, primary, Brambilla, Cecilia, additional, Rice, Alexandra, additional, Robertus, Jan Lukas, additional, MacMahon, Suzanne, additional, Thompson, Lisa, additional, Antoniou, Georgios, additional, Popat, Sanjay, additional, and Nicholson, Andrew, additional

Published
2021
Full Text
View/download PDF

212. HALT: targeted therapy with or without dose-intensified radiotherapy in oligo-progressive disease in oncogene addicted lung tumours

Author

McDonald, Fiona, primary, Guckenberger, Matthias, additional, Popat, Sanjay, additional, Faivre-Finn, Corinne, additional, Andratschke, Nicolaus, additional, Riddell, Angela, additional, Hanna, Gerard, additional, Prakash, Vineet, additional, Nair, Arjun, additional, Diez, Patricia, additional, Patel, Priyanka, additional, Kilburn, Lucy, additional, Toms, Christy, additional, and Bliss, Judith, additional

Published
2021
Full Text
View/download PDF

214. Biomarker Testing for People With Advanced Lung Cancer in England

Author

Adizie, Jana B., primary, Tweedie, Judith, additional, Khakwani, Aamir, additional, Peach, Emily, additional, Hubbard, Richard, additional, Wood, Natasha, additional, Gosney, John R., additional, Harden, Susan V., additional, Beckett, Paul, additional, Popat, Sanjay, additional, and Navani, Neal, additional

Published
2021
Full Text
View/download PDF

215. HER3 expression and MEK activation in non-small-cell lung carcinoma

Author

Manickavasagar, Thubeena, primary, Yuan, Wei, additional, Carreira, Suzanne, additional, Gurel, Bora, additional, Miranda, Susana, additional, Ferreira, Ana, additional, Crespo, Mateus, additional, Riisnaes, Ruth, additional, Baker, Chloe, additional, O’Brien, Mary, additional, Bhosle, Jaishree, additional, Popat, Sanjay, additional, Banerji, Udai, additional, Lopez, Juanita, additional, Bono, Johann de, additional, and Minchom, Anna, additional

Published
2021
Full Text
View/download PDF

216. Activity of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwinG).

Author

Miura, Satoru, primary, Hsia, Te-Chun, additional, Hung, Jen-Yu, additional, Jung, Hyun Ae, additional, Shih, Jin-Yuan, additional, Park, Cheol-Kyu, additional, Lee, Seung Hyeun, additional, Okamoto, Tatsuro, additional, Ahn, Hee Kyung, additional, Lee, Yong Chul, additional, Sato, Yuki, additional, Lee, Sung Sook, additional, Mascaux, Celine, additional, Daoud, Hasan, additional, Maerten, Angela, additional, and Popat, Sanjay, additional

Published
2021
Full Text
View/download PDF

218. PP01.24 FURVENT: Phase 3 trial testing furmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertions (FURMO-004)

Author

Spira, Alexander, Cho, Byoung Chul, Felip, Enriqueta, Garon, Edward B., Goto, Koichi, Johnson, Melissa, Leighl, Natasha, Passaro, Antonio, Planchard, David, Popat, Sanjay, Yang, James, Lu, Xiaoqian, Jiang, Yong, Huang, Jack, Lam, Morgan, Kowanetz, Marcin, Wang, Shirley, Le, John, Hsu, Jerry Y., and Zhou, Cai-Cun

Published
2024
Full Text
View/download PDF

219. PPD01.02 Repotrectinib in Patients With ROS1Fusion-Positive (ROS1+) NSCLC: Update From the Pivotal Phase 1/2 TRIDENT-1 Trial

Author

Drilon, Alexander, Camidge, D. Ross, Lin, Jessica J., Kim, Sang-We, Solomon, Benjamin, Dziadziuszko, Rafal, Besse, Benjamin, Goto, Koichi, Johannes de Langen, Adrianus, Wolf, Jürgen, Lee, Ki Hyeong, Popat, Sanjay, Springfeld, Christoph, Nagasaka, Misako, Felip, Enriqueta, Yang, Nong, Lu, Shun, Kao, Steven, Velcheti, Vamsidhar, Cheema, Parneet, Stopatschinskaja, Shanna, Mehta, Minal, Trone, Denise, Ades, Felipe, Calvet, Christophe Y., and Cho, Byoung Chul

Published
2024
Full Text
View/download PDF

226. Indirect comparisons of brigatinib and alectinib for front-line -positive non-small-cell lung cancer.

Author

Reckamp, Karen L, Lin, Huamao M, Cranmer, Holly, Wu, Yanyu, Zhang, Pingkuan, Walton, Laura J, Kay, Stephen, Cichewicz, Allie, Neupane, Binod, Fahrbach, Kyle, Popat, Sanjay, and Camidge, D Ross

Subjects
LUNG cancer, DISEASE progression, PROTEIN kinase inhibitors, HETEROCYCLIC compounds, ORGANOPHOSPHORUS compounds, LUNG tumors, PIPERIDINE, RESEARCH funding
Abstract

Aim: To conduct an indirect treatment comparison (ITC) of the relative efficacy of brigatinib and alectinib for progression-free survival in people with tyrosine kinase inhibitor (TKI)-naive ALK-positive non-small-cell lung cancer (NSCLC). Methods: Final aggregate and patient-level data from the ALTA-1L trial comparing brigatinib to crizotinib and published aggregate data from ALEX (comparing alectinib to crizotinib) were contrasted using Bucher ITC and matching-adjusted indirect comparisons (MAICs). Results: No statistically significant differences were identified between brigatinib and alectinib in reducing the risk of disease progression overall and in patients with baseline central nervous system metastases. Conclusion: Brigatinib appeared similar to alectinib in reducing risk of disease progression for people with TKI-naive ALK-positive NSCLC. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

228. Genomic mapping identifies multiple therapeutic pathways in malignant mesothelioma

Author

Nastase, Anca, Mandal, Amit, Lu, Shir Kiong, Anbunathan, Hima, Morris-Rosendahl, Deborah, Zhang, Yu Zhi, Sun, Xiao-Ming, Gennatas, Spyridon, Rintoul, Robert C, Edwards, Matthew, Bowman, Alex, Chernova, Tatyana, Benepal, Tim, Lim, Eric, Newman Taylor, Anthony, Nicholson, Andrew G, Popat, Sanjay, Willis, Anne E, MacFarlane, Marion, Lathrop, Mark, Bowcock, Anne M, Moffatt, Miriam F, and Cookson, William OCM

Abstract

Malignant pleural mesothelioma (MPM) is an aggressive malignancy associated with asbestos exposure. It shows limited responses to all treatments. Although 20% of tumours may transiently regress after checkpoint immunotherapy, predictors of response are unknown. The molecular landscape is of low complexity but recurrent lesions have not yet defined effective therapeutic targets. In order to comprehensively map genomic alterations, we combined copy-number analysis from SNP arrays with targeted sequencing of tumours from 121 patients. We found previously unrecognised deletions in the tumour suppressor RB1 in 26% of cases. These combined with CDKN2A and TP53 lesions affected the RB tumour suppressor pathway in 65% of tumours. We show here therapeutic avenues downstream of RB1 by finding micromolar half maximal inhibitory concentrations (IC50s) of PLK1, CHEK1 and Aurora Kinase inhibitors in MPM cell lines. Non-overlapping defects in Hippo pathways ( RASSF7 amplification, NF2 , LATS1 and LATS2 mutations) were present in 48% of tumours, accompanied by micromolar IC50s to the YAP1 inhibitor Verteporfin. Loss of a 240Kb locus containing SUFU was observed in 21% of tumours, accompanied by disordered expression of Hedgehog pathway genes. SUFU depletion was reproducibly associated with reduced transcription of T-cell and macrophage regulators, and increased transcription of the immune checkpoint inhibitor VISTA. In half of all MPM, CDKN2A deletions were accompanied by loss of Interferon Type I genes. The presence of dysregulated Hedgehog immune transcription and loss of Type I Interferons indicate novel approaches to immunotherapy.

Published
2020
Full Text
View/download PDF

233. CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations

Author

Felip, Enriqueta, Ardizzoni, Andrea, Ciuleanu, Tudor, Cobo, Manuel, Laktionov, Konstantin, Szilasi, Maria, Califano, Raffaele, Carcereny, Enric, Griffiths, Richard, Paz-Ares, Luis, Duchnowska, Renata, Alonso Garcia, Miriam, Isla, Dolores, Jassem, Jacek, Appel, Wiebke, Milanowski, Janusz, Van Meerbeeck, Jan P., Wolf, Juergen, Li, Ang, Acevedo, Angelic, Popat, Sanjay, Felip, Enriqueta, Ardizzoni, Andrea, Ciuleanu, Tudor, Cobo, Manuel, Laktionov, Konstantin, Szilasi, Maria, Califano, Raffaele, Carcereny, Enric, Griffiths, Richard, Paz-Ares, Luis, Duchnowska, Renata, Alonso Garcia, Miriam, Isla, Dolores, Jassem, Jacek, Appel, Wiebke, Milanowski, Janusz, Van Meerbeeck, Jan P., Wolf, Juergen, Li, Ang, Acevedo, Angelic, and Popat, Sanjay

Abstract

Background: CheckMate 171 (NCT02409368) is an open-label, multicentre, phase 2 trial of nivolumab in previously treated advanced squamous non-small cell lung cancer (NSCLC), conducted as part of a post-approval commitment to the European Medicines Agency (EMA). We report outcomes from this trial. Methods: Patients with Eastern Cooperative Oncology Group performance status (ECOG PS) 0e2 and disease progression during/after >= 1 systemic treatment (>= 1 being platinum-based chemotherapy) for advanced or metastatic disease were treated with nivolumab 3 mg/kg every 2 weeks until progression or unacceptable toxicity. The primary end-point was incidence of grade 3-4 treatment-related select adverse events (AEs). Other end-points included overall survival (OS) and safety. Results: Of 811 patients treated, 103 had ECOG PS 2; 278 were aged >= 70 years and 125 were >= 75 years of age. Minimum follow-up was similar to 18 months. Safety was similar across populations; the most frequent grade 3-4 treatment-related select AEs in all treated patients were diarrhoea (1%), increased alanine aminotransferase (ALT, 1%), pneumonitis (0.7%), colitis (0.6%) and increased aspartate aminotransferase (AST, 0.5%). Median OS was similar in all treated patients and those aged >= 70 and >= 75: 10.0 months, 10.0 months and 11.2 months, respectively. Median OS was 5.2 months in patients with ECOG PS 2. Conclusion: These results suggest that nivolumab is well tolerated and active in patients with advanced, relapsed squamous NSCLC, including the elderly, with OS outcomes consistent with phase 3 data. In patients with ECOG PS 2, nivolumab had similar tolerability, but outcomes were worse, as expected in this difficult-to-treat, poor prognosis population. (C) 2019 The Authors. Published by Elsevier Ltd.

Published
2020

234. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

Author

Baas, Paul, primary, Scherpereel, Arnaud, additional, Nowak, Anna K, additional, Fujimoto, Nobukazu, additional, Peters, Solange, additional, Tsao, Anne S, additional, Mansfield, Aaron S, additional, Popat, Sanjay, additional, Jahan, Thierry, additional, Antonia, Scott, additional, Oulkhouir, Youssef, additional, Bautista, Yolanda, additional, Cornelissen, Robin, additional, Greillier, Laurent, additional, Grossi, Francesco, additional, Kowalski, Dariusz, additional, Rodríguez-Cid, Jerónimo, additional, Aanur, Praveen, additional, Oukessou, Abderrahim, additional, Baudelet, Christine, additional, and Zalcman, Gérard, additional

Published
2021
Full Text
View/download PDF

236. Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease

Author

Collins, Dearbhaile Catherine, primary, Sundar, Raghav, additional, Constantinidou, Anastasia, additional, Dolling, David, additional, Yap, Timothy Anthony, additional, Popat, Sanjay, additional, O’Brien, Mary E., additional, Banerji, Udai, additional, de Bono, Johann Sebastian, additional, Lopez, Juanita Suzanne, additional, Tunariu, Nina, additional, and Minchom, Anna, additional

Published
2020
Full Text
View/download PDF

238. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

Author

Camidge, D. Ross, primary, Kim, Hye Ryun, additional, Ahn, Myung-Ju, additional, Yang, James C. H., additional, Han, Ji-Youn, additional, Hochmair, Maximilian J., additional, Lee, Ki Hyeong, additional, Delmonte, Angelo, additional, García Campelo, Maria Rosario, additional, Kim, Dong-Wan, additional, Griesinger, Frank, additional, Felip, Enriqueta, additional, Califano, Raffaele, additional, Spira, Alexander, additional, Gettinger, Scott N., additional, Tiseo, Marcello, additional, Lin, Huamao M., additional, Gupta, Neeraj, additional, Hanley, Michael J., additional, Ni, Quanhong, additional, Zhang, Pingkuan, additional, and Popat, Sanjay, additional

Published
2020
Full Text
View/download PDF

243. 1 - Prediction of next generation sequencing test failure in lung adenocarcinoma in a genomic laboratory hub setting

Author

Zhang, Yu Zhi, Sherlock, Stuart, MacMahon, Suzanne, Brambilla, Cecilia, Rice, Alexandra, Robertus, Jan Lukas, Wassilew, Katharina, Lim, Eric, Begum, Sofina, Buderi, Silviu, Jordan, Simon, Anikin, Vladimir, Finch, Jonathan, Asadi, Nizar, Beddow, Emma, Garner, Justin L, Morjaria, Jaymin, Lee, Richard, McDonald, Fiona, Antoniou, Georgios, Ridge, Carole, Padley, Simon, Dalal, Paras, Morris-Rosendahl, Deborah, Valganon-Petrizan, Mikel, Shah, Pallav L, Devaraj, Anand, Popat, Sanjay, and Nicholson, Andrew G

Published
2023
Full Text
View/download PDF

249. NTRK gene fusion testing and management in lung cancer.

Author

Repetto, Matteo, Chiara Garassino, Marina, Loong, Herbert H., Lopez-Rios, Fernando, Mok, Tony, Peters, Solange, Planchard, David, Popat, Sanjay, Rudzinski, Erin R., Drilon, Alexander, and Zhou, Caicun

Abstract

• NTRK gene fusions are oncogenic drivers in NSCLC targetable by TRK inhibitors. • It is recommended to identify patients who may benefit from targeted treatment. • RNA-based NGS is considered to be the gold standard testing method. Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are recurrent oncogenic drivers found in a variety of solid tumours, including lung cancer. Several tropomyosin receptor kinase (TRK) inhibitors have been developed to treat tumours with NTRK gene fusions. Larotrectinib and entrectinib are first-generation TRK inhibitors that have demonstrated efficacy in patients with TRK fusion lung cancers. Genomic testing is recommended for all patients with metastatic non-small cell lung cancer for optimal drug therapy selection. Multiple testing methods can be employed to identify NTRK gene fusions in the clinic and each has its own advantages and limitations. Among these assays, RNA-based next-generation sequencing (NGS) can be considered a gold standard for detecting NTRK gene fusions; however, several alternatives with minimally acceptable sensitivity and specificity are also available in areas where widespread access to NGS is unfeasible. This review highlights the importance of testing for NTRK gene fusions in lung cancer, ideally using the gold-standard method of RNA-based NGS, the various assays that are available, and treatment algorithms for patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results